1 min read
Add as a preferred source on GoogleAura Biosciences Posts $0.29 GAAP Loss Per Share for Q3 2026
The company had $297.2 million in cash, cash equivalents and marketable securities as of Sept. 30 and said it believes those resources can fund operations into the first half of 2029.
Aura Biosciences, Inc. posted a GAAP loss of $0.29 per share for the third quarter of 2026. Its cash, cash equivalents and marketable securities totaled $297.2 million as of Sept. 30.
The company said it believes those resources are sufficient to fund operations into the first half of 2029.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.